Compare Costco Wholesale Corporation (COST) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Costco Wholesale Corporation trades at $920.03 (market cap $408.78B), while Inovio Pharmaceuticals Inc trades at $1.17 (market cap $95.85M). The key difference: Costco Wholesale Corporation is far larger — about 4264.8× Inovio Pharmaceuticals Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| COST | INO | |
|---|---|---|
Market Cap | $408.78B | $95.85M |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $2.87 |
52-Week Low | $849.63 | $1.05 |
Enterprise Value | $396.92B | $66.86M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $923.9, down 0.27% with bearish technical signals but strong fundamentals. The stock shows consistent revenue growth, reaching $275.24B in 2025 with net income of $8.10B. Recent March sales surged 11.3% year-over-year to $28.41B, indicating robust business momentum. Analyst consensus remains strongly bullish with 65.5% buy ratings and a $1,120 price target, though valuation metrics appear elevated with P/E at 46.37.
The investment case balances premium valuation against exceptional operational execution. Membership fee increases and expanding warehouse network drive profitability, but high P/E ratio requires sustained growth. Key risks include competitive pressure and economic sensitivity, while institutional accumulation supports long-term confidence.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
